Ehret Megan J, Fuller Matthew A
Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Rd., Brecksville, OH 44141-3204, USA.
Ann Pharmacother. 2004 Dec;38(12):2122-7. doi: 10.1345/aph.1E085. Epub 2004 Nov 2.
To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia.
Information was selected from PubMed (1965-July 2004). Applicable scientific posters were also used.
All published information on risperidone LA was considered. Material providing a comprehensive description was considered.
Risperidone LA is the first long-acting, injectable atypical antipsychotic. It is dosed at 25-50 mg every 2 weeks. Adverse effects are similar to those seen with oral risperidone. A short-term study showed that risperidone LA is better than placebo in reducing the signs and symptoms of schizophrenia, and a long-term trial showed that stable schizophrenic patients can be switched from either oral or other injectable antipsychotic medications to risperidone LA.
Risperidone LA is efficacious and safe in the treatment of schizophrenia.
综述长效利培酮治疗精神分裂症的药理学、药代动力学、临床疗效及安全性。
从PubMed（1965年 - 2004年7月）中选取信息。也使用了相关的科学海报。
纳入所有已发表的关于长效利培酮的信息。选取能提供全面描述的资料。
长效利培酮是首个长效注射用非典型抗精神病药物。每2周给药25 - 50毫克。不良反应与口服利培酮相似。一项短期研究表明，长效利培酮在减轻精神分裂症的体征和症状方面优于安慰剂，一项长期试验表明，稳定的精神分裂症患者可从口服或其他注射用抗精神病药物转换为使用长效利培酮。
长效利培酮治疗精神分裂症有效且安全。
